KEEP UP WITH THE LATEST IN INDUSTRY NEWS!
From news about new medicines, pharmacy business insights, and the pharmaceutical industry in general—this is your source!
Drug Topics articles
- <![CDATA[Wound Care in Community Pharmacy: Practical Guidance for Frontline Teams]]> April 19, 2026
- <![CDATA[FAQ: How Insulin Therapy Is Managed Across the Care Continuum]]> April 18, 2026
- <![CDATA[Different Messaging for Older Adults Can Increase Vaccination Rates]]> April 17, 2026
- <![CDATA[Billing Gaps Devalue the Patient Care Clinical Pharmacists Provide]]> April 17, 2026
- <![CDATA[Leading Obesity Experts Deem Obesity Medications as Safe and Effective]]> April 17, 2026
- <![CDATA[Medication Adherence Lowers Cost, ER Visits Among Patients with CVD]]> April 17, 2026
- <![CDATA[3 Moves Every Pharmacy Should Make Now to Regain Operational Control]]> April 17, 2026
- <![CDATA[The Hidden Cost of Inconsistent Procurement Practices Across Multi-Location Pharmacies]]> April 17, 2026
- <![CDATA[Pharmacies Must Market Their Clinical Services for Sustainability]]> April 16, 2026
- <![CDATA[What Pharmacies Need to Know About FDA Shift to 12-Digit NDCs]]> April 16, 2026
Pharmacy Times articles
- <![CDATA[AAN 2026: From Migraines to Alzheimer, How the Menopausal Transition Affects Neurological Risk in Women]]> April 19, 2026
- <![CDATA[AAN 2026: Sex and Gender Gaps in TBI Care, What Pharmacists and Clinicians Need to Know]]> April 19, 2026
- <![CDATA[Q&A: Understanding Pneumococcal Disease Burden and Vaccine Opportunities]]> April 17, 2026
- <![CDATA[FDA Approves Sotyktu From Bristol Myers Squibb]]> April 17, 2026
- <![CDATA[De-escalating Treatment in HER2-Positive Breast Cancer: Doing More With Less ]]> April 17, 2026
- <![CDATA[Optimizing Specialty Medication Access in Community Pharmacy: A Practical Workflow Approach]]> April 17, 2026
- <![CDATA[From Burnout to Balance: How Walgreens' Hybrid Model Is Addressing the Pharmacy ]]> April 17, 2026
- <![CDATA[Oncology Pulse Points: ASCO WBC Growth Factors Guidelines Update]]> April 17, 2026
- <![CDATA[SIDP Is Shaping the Next Era of Infectious Diseases Treatment]]> April 17, 2026
- <![CDATA[Impact of Overall Survival Data on Immunotherapy Selection in Endometrial Cancer]]> April 17, 2026
Helping You Navigate the Returns Process!
Pedigree Statement
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with it’s clients…
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with its clients. This is to ensure that the reverse distribution portion of the supply chain that we service keeps its functionality and integrity for our customers and the public.
Several pedigree and distribution level issues have been raised in the industry. Discounted, indigent-pricing, short dated, bulk purchase, secondary distribution, or DSCSA non-compliant sales could affect the credit available for a product based on a manufacturers determination. We ask that you do not return these products for credit as they are not eligible in most cases. Flash Returns LLC may choose to dispose of these on the pharmacies behalf at no charge if the cost is low relative to the return. Most customers purchasing products from reputable wholesalers will not encounter these issues, however all pharmacies are asked to acknowledge our policy on pedigree and legitimacy of product here and by signing the PSA before a return is initiated.
Some manufacturers may require proof the price paid for a product and what wholesaler distributed the product. Issues causing triggering this could be: bulk or large quantities of single items or lots, or products purchased speculatively. In some cases we may request invoices from the customer to ensure Flash Returns or manufacturer policy is being met. If none are available or if the information isn’t accepted by the manufacturer it could cause the return to be non-returnable.
Flash Returns, LLC cannot guarantee or be liable for the value or credit for products that were purchased outside of manufacturer accepted distribution channels. This could include products: purchased from a wholesaler that is not an approved vendor, products not purchased directly from a particular manufacturer, purchased on a speculative basis, diverted or counterfeit products, foreign products, and any product purchased on a non-returnable basis, including short-dated product purchased at discounted pricing.
At any time, Flash Returns, LLC or a manufacturer may require invoices or pedigree information demonstrating proof of purchase. If product has been shipped by Flash Returns, LLC or the Customer to a manufacturer or their agent, Flash Returns, LLC cannot guarantee or facilitate the return of product to the Customer. Manufacturers reverse the right to destroy product they deem not credit worthy or suspect. Manufacturers agreeing to return product to customers will do so at the customers expense. Flash Returns, LLC shall not be responsible for reimbursing a Customer for such product.
If Customer is unable to have product returned within 21 days, product is subject to be destroyed without any payment or credit issued to Customer. In any dispute, failure by Customer to provide invoices for a product or pedigree if requested shall release Flash Returns, LLC from any and all liability of products involved in dispute including the full value of the product. More information on drug pedigrees is available on the FDA website at:
Pedigree Statement
P: 833.553.5274
E: SignUp@FlashReturns.com
